Io­n­is un­veils pos­i­tive PhII da­ta for in-house rare dis­ease drug, paving way to block­buster ri­val­ry with Take­da

One of the mid-stage an­ti­sense drugs for rare, non-neu­ro­log­i­cal dis­eases that Brett Mo­nia boast­ed about at JP Mor­gan ear­li­er this year has de­liv­ered a sol­id …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER